
Boehringer Ingelheim Boosts I&I Portfolio With $357M in Biobucks for Cue
Boehringer Ingelheim is fronting $12 million to license Cue Biopharma’s investigational B cell depletion therapy for autoimmune diseases, the German biopharma announced on Monday. The star of this back-heavy, multi-year deal is Cue’s CUE-501, a preclinical …